Metraipolis › archive › dc_91ce6c2dbe64

Redifferentiation therapy with selpercatinib in RET-fusion-positive advanced thyroid carcinoma: a case report and literature review — Europe PMC PMID:42444822

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42444822
DOI
10.3389/fonc.2026.1819030
License (as archived)
solo-consultazione
Archived
2026-10-31T07:09:40.142Z
SHA-256 of the archived text
99d58125f7f8d71f531b52f6472495744d09ca7644ad30eab57525ff4496dd1f
Stable URL of this page
https://metraipolis.com/documento/dc_91ce6c2dbe64

How to cite

Redifferentiation therapy with selpercatinib in RET-fusion-positive advanced thyroid carcinoma: a case report and literature review — Europe PMC PMID:42444822 — Europe PMC (en), https://europepmc.org/article/MED/42444822 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_91ce6c2dbe64 (Metraipolis archive dc_91ce6c2dbe64, sha256 99d58125f7f8d71f531b52f6472495744d09ca7644ad30eab57525ff4496dd1f)
BibTeX
@misc{dc91ce6c2dbe64,
  title = {Redifferentiation therapy with selpercatinib in RET-fusion-positive advanced thyroid carcinoma: a case report and literature review — Europe PMC PMID:42444822},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42444822},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_91ce6c2dbe64; sha256 99d58125f7f8d71f531b52f6472495744d09ca7644ad30eab57525ff4496dd1f},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42444822. Agents can read the archived copy with the MCP tool read_document.